Abstract
Aims
This study aimed to evaluate the incidence and prevalence of blindness, sight impairment, and other visual acuity (VA) states in patients receiving ranibizumab for neovascular age-related macular degeneration (nAMD) in Gloucestershire.
Methods
Serial VA and injection data for all treatment-naive patients receiving their first intravitreal injections of ranibizumab for nAMD in the Gloucestershire National Health Service Ophthalmology department between 2008 and 2010 were extracted from an electronic medical record system.
Results
The prevalence of blindness (VA in the better-seeing eye ≤25 Early Treatment Diabetic Retinopathy Study (ETDRS) letters) at the time of first intravitreal injection was 0.8%, increasing to 3.5% after 3 years. The prevalence of sight impairment (VA in the better-seeing eye 26–39 ETDRS letters) increased from 4.1% at baseline to 5.5% after 3 years. The incidence of initiating ranibizumab treatment for nAMD in people aged ≥50 years in Gloucestershire was 111 people per 100 000 population in 2009, and 97 people in 2010. The incidence of patients meeting the visual criteria for blindness and sight impairment registration from treated nAMD in people aged ≥50 years in Gloucestershire was 3.5 and 9.7 people, respectively per 100 000 population in 2010.
Conclusion
This is the first real-world study on the incidence and prevalence of eligibility for blindness and sight impairment registration in treated nAMD in the UK based on VA data. The incidence and prevalence of eligibility for certification of blindness or sight impairment in patients treated with ranibizumab for nAMD is low in Gloucestershire, with only 3.6% of the incident population progressing to blindness in 2010.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Buch H, Vinding T, La Cour M, Appleyard M, Jensen GB, Nielsen NV . Prevalence and causes of visual impairment and blindness among 9980 Scandinavian adults. Ophthalmology 2004; 111 (1): 53–61.
Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004; 82 (11): 844–851.
Bressler NM . Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291 (15): 1900–1901.
Bunce C, Wormald R . Causes of blind certification in England and Wales: April 1999 - March 2000. Eye 2008; 22: 905–911.
Skaat A, Chetrit A, Belkin M, Kalter-Leibovici O . Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 2012; 153 (2): 214–221.
Minassian DC, Reidy A, Lightstone A, Desai P . Modelling the prevalence of age-related macular degeneration (2010-2020) in the UK: expected impact of anti-vascular endothelial growth factor (VEGF) therapy. Br J Ophthalmol 2011; 95 (10): 1433–1436.
Rein DB, Wittenborn JS, Zhang X, Honeycutt AA, Lesesne SB, Saaddine J . Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments. Arch Ophthalmol 2009; 127 (4): 533–540.
Campbell JP, Bressler SB, Bressler NM . Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol 2012; 130 (6): 794–795.
Bloch S, Larsen M, Munch I . Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153 (2): 209–213.
Rostron E, McKibbin M . Visual impairment certification secondary to ARMD in Leeds 2005-2010: is the incidence falling? Eye 2012; 26 (7): 933–936.
Bressler NM, Doan QV, Varma R, Lee PP, Suner IJ, Dolan C et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularisation: non-Hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol 2011; 129 (6): 709–717.
Robinson R, Deutsch J, Jones H, Youngson-Reilly S, Hamlin D, Dhurjon L . Unrecognised and unregistered visual impairment. Br J Ophthalmol 1994; 78 (10): 736–740.
Barry R, Murray P . Unregistered visual impairment: is registration a failing system? Br J Ophthalmol 2005; 89 (8): 995–998.
Malik AN, Bunce C, Wormald R, Suleman M, Stratton I, Muir Gray JA . Geographical variation in certification rates of blindness and sight impairment in England, 2008-2009. BMJ Open 2012; 2 (6).
Linder M, Chang TS, Scott IU, Hay D, Chambers K, Sibley LM et al. Validity of the visual function index (VF-14) in patients with retinal disease. Arch Ophthalmol 1999; 117 (12): 1611–1616.
Bressler NM, Chang TS, Suner IJ, Fine JT, Dolan CM, Ward J et al. Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA AND ANCHOR. Ophthalmology 2010; 117 (4): 747–756.
Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes. Ophthalmology 2009; 116: e1–e8.
TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. Arch Ophthalmol 1999; 117: 1329–1345.
TAP and VIP Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularisation secondary to age-related macular degeneration: TAP and VIP Report No. 1. Am J Ophthalmol 2003; 136: 407–418.
Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S et al. Randomised, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145 (2): 239–248.
Writing Committee for the UK Age-Related Macular Degeneration EMR Users' Group. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. Ophthalmology 2014; 121 (5): 1092–1101.
Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K . Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA and HORIZON. Ophthalmology 2013; 120: 2292–2299.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
RJ is a director of Medisoft Limited, the electronic medical record used in this study. The remaining authors declare no conflict of interest.
Additional information
Author contributions
MB collected and analysed the data, and drafted the paper; AL analysed the data; RH collected the data; AT and RJ devised the concept, and redrafted and edited the paper; QM, EF, and AS edited the paper.
Supplementary Information accompanies this paper on Eye website
Supplementary information
Rights and permissions
About this article
Cite this article
Buckle, M., Lee, A., Mohamed, Q. et al. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. Eye 29, 403–408 (2015). https://doi.org/10.1038/eye.2014.296
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2014.296
This article is cited by
-
Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes
Quality of Life Research (2017)
-
Certification figures and their accuracy
Eye (2015)
